Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development

A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less

1997 • 2,670 citations

Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy

1998 • 861 citations

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1996 • 776 citations

Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy

1995 • 637 citations

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

1996 • 411 citations

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

1995 • 397 citations

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

1997 • 380 citations

The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients

1996 • 302 citations

Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents

1988 • 257 citations

Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy

1996 • 247 citations

Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89

1997 • 225 citations

9-(2-phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys

1991 • 214 citations

Combination Therapy with Zidovudine and Didanosine Selects for Drug-Resistant Human Immunodeficiency Virus Type 1 Strains with Unique Patterns of pol Gene Mutations

1994 • 208 citations

Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients

1998 • 199 citations

Structural Mechanisms of HIV Drug Resistance

1996 • 177 citations

Cyclic Urea Amides: HIV-1 Protease Inhibitors with Low Nanomolar Potency against both Wild Type and Protease Inhibitor Resistant Mutants of HIV

1997 • 115 citations

Human Immunodeficiency Virus Type 1 Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment

1998 • 103 citations

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine

1995 • 85 citations

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication

1995 • 85 citations

Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.

1996 • 83 citations

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

1996 • 75 citations

Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease

1997 • 73 citations

Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates

1995 • 70 citations

The not-so-great escape

1995 • 69 citations

Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro

1996 • 64 citations

Quantification of HIV-1 viral load in lymphoid and blood cells

1997 • 63 citations

The Daunting Challenge of Keeping HIV Suppressed

1997 • 55 citations

Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266

1996 • 55 citations

New Series of Potent, Orally Bioavailable, Non-Peptidic Cyclic Sulfones as HIV-1 Protease Inhibitors

1996 • 55 citations

Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction.

1995 • 53 citations

Characterisation of Foscarnet-Resistant Strains of Human Immunodeficiency Virus Type 1

1995 • 39 citations

Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine

1989 • 30 citations

Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice

1997 • 29 citations

In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine

1997 • 27 citations

Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates

1994 • 18 citations

Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine

1996 • 11 citations

Antiviral Activity of DG-35-VIII, a Potent Inhibitor of the Protease of Human Immunodeficiency Virus

1997 • 6 citations